Major Health Plan Expands DarioHealth Partnership, Potentially Tripling Revenue Opportunity
DRIO is trading near its 52-week low of $5.845 (13% above the low).
Summary
A top national health plan has extended its mental health agreement with DarioHealth and expanded the partnership to include cardiometabolic care, specifically a hypertension solution. This marks the third health plan customer to broaden its deployment beyond an initial condition. This positive development follows DarioHealth's Q1 2026 report, which showed a 17.3% year-over-year revenue decrease, significant cash burn, and a going concern warning. The expansion has the potential to approximately triple DarioHealth's revenue opportunity under this customer relationship, validating the company's multi-condition growth strategy. Revenue contribution from this expanded program is expected in 2026, with higher impact in 2027 onward.
At the time of this announcement, DRIO was trading at $6.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.4M. The 52-week trading range was $5.84 to $17.74. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.